



ASX Announcement

12 December 2019

Release of Shares from Voluntary Escrow

Creso Pharma Limited (ASX: “CPH”, the “Company” or “Creso”) advises in accordance with Listing Rule 3.10A, that 2,053,043 fully paid ordinary shares (“Shares”) and 303,039 Performance Shares will be released from voluntary escrow on Friday, 20 December 2019.

The securities to be released from voluntary escrow are comprised of:

- a) 2,053,043 Shares of the 8,212,121 Shares issued to the vendors of Kunna Canada Ltd upon the completion of the Company’s acquisition of Kunna Canada Ltd on 20 December 2018; and
- b) 303,039 Performance Shares of the 1,212,120 Performance Shares issued to the vendors of Kunna Canada Ltd subject to vesting conditions.

The Company applied for, and was subsequently granted, quotation of the Shares on 20 December 2018. Holding locks applicable to the abovementioned shares will be lifted prior to the commencement of trade on Friday, 20 December 2019.

Following the expiry of escrow restrictions on the above securities, 500,000 Shares remain subject to escrow restrictions until 16 January 2020.

Authority and Contact Details

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

Corporate Enquiries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney NSW 2000
E: info@everblucapital.com
P: +61 2 8249 000



About Creso Pharma Ltd

(www.cresopharma.com)

Creso brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.